India Glycols Ltd Q1FY26 – Chemicals, Cocktails & Customs Duty: ₹73 Cr PAT, Ethanol Overdrive & Excise Drama
1. At a Glance
India Glycols Ltd (NSE: INDIAGLYCO, CMP: ₹853) is that rare desi hybrid that makes both solvents for paint companies and vodka for paint-thinners-turned-partygoers. With a market cap of ₹5,299 crore, the company posted Q1FY26 revenue of ₹1,040 crore (+7.4% YoY) and PAT of ₹73.2 crore (+21.3% YoY). ROE is 11.1%, ROCE 12.4%, debt is a chunky ₹1,892 crore (0.84x D/E), and P/E sits at 21.7x — basically cheaper than United Breweries’ froth but pricier than Tilaknagar’s desi tharra. The 6-month return is 53.8% (cheers 🥂), but the last 3 months saw a –16.6% hangover. Dividend yield at 0.59% is barely enough for one quarter peg.
2. Introduction
If Reliance is “Oil to Jio,” then India Glycols is “Grain to Gin.” Born in 1988, the company calls itself “green-tech driven.” Translation: they make chemicals from bio-based feedstocks instead of petro-based, which sounds eco-friendly until you realize they’re also India’s largest country liquor bottler in tetra packs.
Their portfolio is like a wedding buffet:
Bulk & Specialty Chemicals for FMCG, paints, autos.
Ethanol for OMCs because petrol apparently needs cocktail mixing too.
IMFL brands like Soulmate Blu (whiskey), Amazing (vodka), and Zumba (rum).
Ennature Biopharma making nutraceutical APIs like lutein and curcumin (basically turmeric capsules with a fancier label).
Geography? 91% domestic, 9% export. Basically, they’re still a ghar-ka-bazaar company. Plants? Gorakhpur, Kashipur, Dehradun — not exactly Basel or Boston, but running at 100% utilization.
In short: one company supplies ethanol to Indian Oil, vodka to Delhi bars, and thiocolchicoside to Europe. Try explaining that combo to a foreign analyst.
3. Business Model – WTF Do They Even Do?
IGL’s model is a bizarre cocktail:
Specialty & Performance Chemicals (64%): Glycols, glycol ethers, acetates, amines, plasticizers. Basically, half of India’s FMCG and paint supply chain runs on this stuff. Think of them as the “Masala Factory” of modern industry.
Spirits (28%): Whiskey, rum, vodka. Market leader in flavored vodka tetra packs (40%+ share). They’re like Bisleri, but for booze.
Ennature Biopharma (7%): APIs, nutraceuticals, carotenoids, liquid nicotine. That one nerdy cousin in the family who does biotech while the rest sell booze.
Industrial Gases: Liquid oxygen at Kashipur (60 MTPD). Because why not sell oxygen along with alcohol?
Revenue split screams dual personality disorder: one foot in the chemical lab, one foot in thekas. But maybe that’s the genius — when industrial demand slows, people still drink.
Would you trust a company that sells both ethanol to OMCs and vodka to the common man? Or is that just vertical integration at its finest?
